Phase II trial of carboplatin in soft-tissue sarcoma

• Published in: American journal of clinical oncology Vol. 13; no. 5; p. 420
• Main Authors: Goldstein, D, Cheuvart, B, Trump, D L, Shiraki, M, Comis, R L, Tormey, D C, Harris, J E, Borden, E C
• Format: Journal Article
• Language: English
• Published: United States 01.10.1990
• Subjects: Adult; Aged; Carboplatin - therapeutic use; Drug Evaluation; Female; Humans; Male; Middle Aged; Remission Induction; Sarcoma - drug therapy; Soft Tissue Neoplasms - drug therapy; United States; United States
• ISSN: 0277-3732
• DOI: 10.1097/00000421-199010000-00011

As part of the Eastern Cooperative Oncology Group program for the assessment of new drugs in sarcomas, a Phase II trial of carboplatin was performed in patients who had received no more than one prior chemotherapy regimen. A total of 50 patients received either 400 mg/m2 or 320 mg/m2 depending on whether they had received prior radiotherapy. A response rate of 16% (95% confidence interval 6-32%) occurred in the 37 patients who had received doxorubicin as their only prior systemic therapy. Three of the six responses were complete and persisted for 7 to 34 months. In contrast none of the 13 patients who received carboplatin after initial progression on doxorubicin and subsequent progression on interferon alpha responded. The overall response rate was therefore 12% (95% confidence interval 5-24%). Toxicity was primarily hematologic, with 14 patients having Eastern Cooperative Oncology Group (ECOG) grade 3 toxicity and no grade 4 or 5 toxicities. In view of the number of complete responses, carboplatin should be studied further in untreated patients with advanced soft tissue sarcoma.